An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Phase 3CompletedNCT02845674

Sun Pharmaceutical Industries Limited258 enrolled

Overview

This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

258

0.09% cyclosporine nanomicellar solution

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completion of Study OTX-101-2016-001 Exclusion Criteria: \-

Adverse Events

Number of subjects reporting any AEs

Time frame: 40 weeks

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.